Lahjavida’s Dye-Drug Conjugates (DDCs) are small-molecule “dye–linker–payload” constructs, conceptually analogous to antibody-drug conjugates (ADCs), which are composed of an antibody, linker, and cytotoxic payload. Like ADCs, DDCs are designed to improve the therapeutic index of potent cancer therapies through targeted delivery. However, DDCs leverage small-molecule dye chemistry rather than antibodies to enable tumor-selective uptake. “We are honored to have our work selected for presentation at AACR, one of the most respected scientific forums in oncology,” said Lyle Small, Founder and Chief Executive Officer of Lahjavida Bio. To learn more about Lahjavida Bio and its Dye-Drug Conjugate platform, visit https://lahjavida.com.

Source: The Herald February 12, 2026 19:04 UTC